We are live on ! Find out more
TWST icon

Twist Bioscience

151.11 USD
+10.31
7.32%
At close Updated Aug 25, 3:49 PM EDT
1 day
7.32%
5 days
18.05%
1 month
74.61%
3 months
132.94%
6 months
204.78%
Year to date
366.53%
1 year
451.7%
5 years
34.5%
10 years
979.36%
 

About: Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Employees: 979

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 33.3%
Neutral 66.7%
Negative 0%
Positive
Seeking Alpha
4 days ago
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)
Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A persist.
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)
Positive
Benzinga
5 days ago
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report
Twist Bioscience Corp (NASDAQ:TWST) shares surged Wednesday after Anthropic named the company an independent evaluator in a new AI-driven protein design campaign.
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report
Positive
Seeking Alpha
11 days ago
Alger Small Cap Growth Fund Q2 2026 Portfolio Review
Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the second quarter of 2026. Nebius Group, Astera Labs, Inc., and Twist Bioscience Corp. were among the top contributors to performance. Insmed Incorporated, Planet Fitness, Inc., and Forte Biosciences Inc. were among the top detractors from performance.
Alger Small Cap Growth Fund Q2 2026 Portfolio Review
Neutral
Seeking Alpha
19 days ago
Artisan Global Discovery Fund Q2 2026 Portfolio Activity
During the quarter, we initiated new positions in Entegris, Cellebrite and C.H. Robinson. In addition to Lattice Semiconductor and Babcock, we added to Games Workshop Group, Tradeweb Markets and Teledyne Technologies during the quarter. In addition to ROBLOX, we ended our investment campaigns in Colliers International and MongoDB.
Artisan Global Discovery Fund Q2 2026 Portfolio Activity
Positive
Seeking Alpha
20 days ago
Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety
Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist's margins continue to improve.
Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety
Neutral
Business Wire
20 days ago
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commissio.
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
Neutral
Business Wire
20 days ago
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by.
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Neutral
Business Wire
21 days ago
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units (“RSUs”) will be granted to 24 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist's Amended and Res.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Neutral
Seeking Alpha
22 days ago
Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript
Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript
Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript
Positive
Benzinga
22 days ago
Twist Bioscience Sees AI Drug Discovery Pipeline Expand
Twist Bioscience Corporation (NASDAQ:TWST) stock is up on Monday as the company reported its fiscal 2026 third-quarter financial results and raised fiscal 2026 guidance.
Twist Bioscience Sees AI Drug Discovery Pipeline Expand
Price charts implemented using Lightweight Charts™